PharmAla Biotech Holdings Inc. is pleased to announce that is has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia, a charity which seeks to alleviate the suffering caused by mental illness in Australia through expanding treatment using psychedelic molecules.
PharmAla Continues to Support Clinical Trials as the Foremost Supplier of GMP LaNeo MDMA in Australia
VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that is has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia, a charity which seeks to alleviate the suffering caused by mental illness in Australia through expanding treatment using psychedelic molecules.
“When MMA approached us a year ago, they did so because they recognized that we were the only entity in the world which had the manufacturing capability – and the operational execution – to deliver MDMA to them along their desired timelines. While the road to this execution wasn’t easy, I’m glad to say that we have delivered,” said Nick Kadysh, Chief Executive Officer of PharmAla. “In the future, we anticipate that Cortexa – our joint venture with Vitura Health – will be more than capable of fulfilling all demand in the Australian market, and without the additional regulatory burden of import/export.”
The contract with Mind Medicine Australia was announced in May of 2022, and is now considered complete. PharmAla remains, at this time, the only publicly traded company in the world to have successfully manufactured GMP MDMA drug product – appropriate for human use – and to have shipped that product to Australia.
Shipment to University of Melbourne
PharmAla is also pleased to announce that it, and its manufacturing partners, have completed shipment of its GMP LaNeo MDMA capsules to the Orygen Institute, affiliated with the University of Melbourne. This shipment represents the first of two shipments which will support a Clinical Trial registered by the Orygen Institute, with the second shipment scheduled for 2024. The contract was previously announced in a press release dated August 22, 2022.
“PharmAla continues to prove that we deliver on our commitments, and do so at the highest levels of regulatory compliance,” said Shane Morris, COO, PharmAla Biotech. “Our best-in-class value chain continues to execute deliveries to customers – even on the other side of the world – and we look forward to expanding our capabilities further in the coming months as Cortexa fully comes online.”
For more info, please see www.PharmAla.ca.
About PharmAla
PharmAla is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is the first publicly-traded company to manufacture clinical-grade MDMA. PharmAla’s research and development unit has completed proof-of-concept research into ALA-002, PharmAla’s lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.
For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Neither the Canadian Securities Exchange (“CSE”) nor the Market Regulator (as that term is defined in the policies of the CSE accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. These statements relate to matters that identify future events or future performance. Often, but not always, forward looking information can be identified by words such as “could”, “pro forma”, “plans”, “expects”, “may”, “will”, “should”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. The forward-looking statements contained herein include, but are not limited to statements regarding: the Company’s objectives and goals; the shipment of MDMA to the University of Sydney and the Company’s contract with the University of Sydney; the Company refiling an amended and restated offering document and corresponding news release to relaunch the LIFE Offering; and the results of the Sydney trial and further research into MDMA based on these results.
These forward-looking statements are based on certain assumptions and estimates of management of the Company at the time such statements were made, including: the Company’s ability to attract and retain qualified members of management to grow the Company’s business and its operations; the Company’s ability to raise any necessary additional capital on reasonable terms to advance the development of the Company’s products; the Company’s ability to effectively manage unanticipated costs and expenses; the Company retaining and supplementing its board of directors and management, or otherwise engaging consultants and advisors having knowledge of the industries (or segments thereof) within which the Company may from time to time participate; current and future members of management abiding by the Company’s business objectives and strategies from time to time established by the Company; the Company’s ability to generate cash flow from operations; future prices and demand for MDXX class molecules and MDMA; the Company’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; future currency exchange rates and interest rates; operating conditions being favourable such that the Company is able to operate in a safe, efficient and effective manner; the Company’s ability to attract and retain skilled personnel; political and regulatory stability; the receipt of governmental, regulatory and third-party approvals, licenses and permits on favourable terms; obtaining required renewals for existing approvals, licenses and permits on favourable terms; requirements under applicable laws; sustained labour stability; stability in financial and capital goods markets; results of operations and performance; industry trends; the market for MDXX class molecules and MDMA will continue to strengthen; the Company having sufficient funds to meet its administrative overhead expenses for the next twelve months; the Authorized Prescriber Program in Australia coming into effect on July 1, 2023; the Company’s ability to fulfil the shipment to the University of Sydney; the Company’s ability to refile an amended and restated offering document and news release to relaunch the LIFE Offering; and the Company’s ability to view the results of the Sydney trial. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements.
Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, without limitation: risks associated with general economic conditions; adverse industry events; income tax and regulatory matters; the Company not utilizing the use of proceeds to expand its operations and products; additional financing may not be available to the Company when required or, if available, the terms of such financing may not be favourable to the Company; fluctuations in demand of MDXX class molecules and MDMA; the Company may not be able to identify, negotiate or finance any future acquisitions successfully, or to integrate such acquisitions with its current business; the Company’s research and development activities are dependent upon the grant of appropriate licenses, concessions, leases, permits and regulatory consents, which may be withdrawn or not granted; the Company’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; the Company and/or its directors and officers may be subject to a variety of legal proceedings, the results of which may have a material adverse effect on the Company’s business; the Company may be adversely affected if potential conflicts of interests involving its directors and officers are not resolved in favour of the Company; dilution from future equity financing could negatively impact holders of the Company’s securities; employee relations; ongoing uncertainties relating to the COVID-19 pandemic; the Authorized Prescriber Program in Australia not coming into effect on July 1, 2022; the Company’s inability to fulfil the shipment to the University of Sydney; the Company’s inability to access the results of the University of Sydney trials; the Company’s inability to refile an amended and restated offering document and news release to relaunch the LIFE Offering; and those factors described under the heading “Risks and Uncertainties” in the Company’s management’s discussion and analysis for the fiscal year ended August 31, 2022, available under the Company’s profile on SEDAR.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company does not undertake to release publicly any revisions for updating any voluntary forward-looking statements, except as required by law.
